|
|
Post by sportsrancho on Sept 30, 2018 16:30:16 GMT -5
Just saw a bayer aspirin advertisement: if your prone to a heart attack ; call 911 and take a bayer aspirin / would not a cricket on your key chain work a hell of a lot faster and more effective.. Popping an aspirin can reduce spread of cancer Aspirin is not just good for treating headaches. Low-dose aspirin can also help in the treatment of cancer and prevent it from spreading through the body, says this new study. Updated: Sep 30, 2018 13:20:44 Asian News International Health,Wellness,Fitness Use of low-dose aspirin helps to prevent heart disease, stroke and cancer, suggests previous research. (Shutterstock) Aspirin may play a life-saving role in the treatment of cancer, finds a study. Peter Elwood of Cardiff University, who directed the study, said the use of low-dose aspirin as a preventive in heart disease, stroke and cancer is well established but evidence is now emerging that the drug may have a valuable role as an additional treatment for cancer too. The systematic review, which looked at the survival of 1,20,000 patients with cancer who took aspirin, compared with 4,00,000 patients who did not, showed that at any time following the diagnosis of some cancers the proportion of patients who were still alive was 20-30% greater in those taking the drug. The spread of cancer to other parts of the body was also substantially reduced in patients using aspirin. One of the colon cancer studies the researchers looked at suggested that a non-diabetic man of about 65 years who takes aspirin would have a prognosis similar to that of a man five years his junior who takes none. For a woman of similar age with colon cancer the addition of aspirin could lead to a similar prognosis of a woman four years younger. Almost half the studies included in the review were of patients with bowel cancer, and most of the other studies were of patients with breast or prostate cancer. There were very few studies of patients with other less common cancers, but on the whole the pooled evidence for all the cancers is suggestive of benefit from aspirin. |
|
|
|
Post by liane on Sept 30, 2018 20:40:02 GMT -5
Just saw a bayer aspirin advertisement: if your prone to a heart attack ; call 911 and take a bayer aspirin / would not a cricket on your key chain work a hell of a lot faster and more effective.. I believe a report/study came out last week that the "Aspirin Theory" does not prevent a heart attack. What just came out is that there is no benefit for taking a daily aspirin for primary prevention of a heart attack - this would be the population who has never had a heart attack. I would still recommend it at the time you are having symptoms of a heart attack as it does antagonize the platelets in the clotting mechanism. |
|
|
|
Post by sla55 on Oct 2, 2018 12:42:59 GMT -5
|
|
|
|
Post by goyocafe on Oct 2, 2018 12:44:42 GMT -5
Crickets
|
|
|
|
Post by nylefty on Oct 2, 2018 13:15:44 GMT -5
Good presentation, but...
Bad mic?
Bad mic technique?
Difficult to understand what he was saying.
|
|
|
|
Post by lakers on Oct 2, 2018 13:19:40 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 2, 2018 13:24:05 GMT -5
MC's presentation at the United event was his best ever, until today when he shot the lights out. In both cases, he sounded as confident and relaxed as he has ever been. He still needs to execute but I believe the company has turned the corner in terms of infrastructure, doing a tier 1 deal with United and Afrezza better positioned than ever (package configuration, insurance coverage, tools for the sales people to help them sell Afrezza...). There will be more deals, no longer any doubt. Check out P. 20 of the presentation, dilution is over and Deerfield is working with Mike because its in their financial best interest to do so. Professional shorts hedged but SI will start to subside. Long road, extremely frustrating at times, but it looks like the young guy from Philly, filled with grit, piss and vinegar is going to make it happen. There will be a replay available, take a listen, you'll be glad you did.
|
|
|
|
Post by buyitonsale on Oct 2, 2018 14:00:37 GMT -5
Money we know of in addition to Afrezza US revenue:
Received from UT - 10M
UT upfront - 45M in 2 weeks
Warrants conversion - 33M within 6 months (if you think if will not happen you are not realistic)
UT milestone - 25M within 12 months
UT Milestone - 25M within 24 months
138M + Afrezza US net sales of 80M minimum for next 24 months = 2+ year runway
The goal is to increase Afrezza world net sales to 100M a year within next 24 months.
Go MNKD!
|
|
|
|
Post by lakers on Oct 2, 2018 15:15:18 GMT -5
Mike spoke about RLS during the Oppenheimer presentation. RLS is manufacturing an inhaled version of cannabinoid for chemo patients dealing with nausea and vomiting. RLS’s treatment will compete with the slower acting oral synthetic, Marinol. Read more: mnkd.proboards.com/thread/9701/mannkind-receptor-life-sciences#ixzz5QXRc9rJXOnly a 5 minute onset compared to 1 to 2-1/2 hours for the other brands listed PLUS no effect on appetite, which the others cannot claim. I'm hoping that ,with Andrea helping with its development, an IND will soon be filed. That may trigger a 2nd milestone payment, too. Read more: mnkd.proboards.com/thread/9701/mannkind-receptor-life-sciences#ixzz5QXS7BiIII think Palonosetron could be a good next application for MNKD as the sister compound Ondansetron has had increasing off label use for many kinds of nausea and vomiting conditions. For example my primary care doc recently offered it to me during a GI viral illness. I have used Ondansetron during a bout of prolonged vertigo and for motion sickness and it is very effective. The oral medication has a 45 minute time to effect and so an inhaled formulation and shorter action would be really nice. Also, constipation is a major side effect after use and I wonder if this might be less with a technosphere product as my guess is this side effect is driven by the serotonin receptors in the gut which might have less impact with an inhaled treatment. Both meds are serotonin 5-HT3 antagonists. Hope I am posting something already on the board. Read more: mnkd.proboards.com/thread/10427/next-potential-apps?page=9#ixzz5So4ygOEaThe folowing shows Tobra-T potential in Bucket-1. Chiesi USA or Dr. Reddy could partner w/ Mnkd Read more: mnkd.proboards.com/user/1882/recent?page=2#ixzz5So6jnY2rseekingalpha.com/article/4204322-mannkind-corporation-mnkd-ceo-michael-castagna-presents-rodman-and-renshaw-20th-annual-global Bucket one turns out to be one of the easiest. It really is known compounds already delivered to the lung. We met with FDA. We saw very clear feedback in terms of the pathway to approval. Limited to no clinical work and really a program that looks at Phase 1 dose finding bioequivalency. So a very efficient program to develop and not a lot of concerns when the drugs are delivered to the lung. You don't have to worry about the dosing as much. And in that particular one, we were looking at the higher end dose saying, can we achieve higher therapeutic levels than we have seen with other Treprostinil relay programs and that was the unmet need we were trying to solve for in addition to the convenience factor. |
|
|
|
Post by lakers on Oct 2, 2018 15:53:52 GMT -5
190. (WO2018175992) RAPID AND CONTROLLED DELIVERY OF COMPOSITIONS WITH RESTORED ENTOURAGE EFFECTS patentscope.wipo.int/search/es/detail.jsf?docId=WO2018175992&recNum=190&office=&queryString=&prevFilter=%26fq%3DICF_M:%22A61K%22&sortOption=Fecha+de+publicación,+orden+descendente&maxRec=1974954 Datos bibliográficos más recientes de la Oficina Internacional Formular observación Enlace permanente Enlace permanente Marcador de página Nº de publicación: WO/2018/175992 Nº de la solicitud internacional: PCT/US2018/024188 Fecha de publicación: 27.09.2018 Fecha de presentación de la solicitud internacional: 23.03.2018 CIP: A61K 47/10 (2017.01) Solicitantes: RECEPTOR LIFE SCIENCES[US/US]; 2578 Constance Dr. W Seattle, Washington 98199, US Personas inventoras: LEONE-BAY, Andrea; US WESNER, Gregory; US Mandataria/o: WINGER, Rachal, C.; US WITTKOPP, Cristina J.; US NGUYEN, Thu; US Datos de prioridad: 62/475,763 23.03.2017 US Título (EN) RAPID AND CONTROLLED DELIVERY OF COMPOSITIONS WITH RESTORED ENTOURAGE EFFECTS (FR) ADMINISTRATION RAPIDE ET CONTRÔLÉE DE COMPOSITIONS AYANT DES EFFETS ENTOURAGE RESTAURÉS Resumen: (EN) Fast-acting oral formulations with restored entourage effects are described. The formulations include beneficial combinations of plant-derived molecules to provide restored entourage effects, and one or more carriers. The carriers can include N-acylated fatty amino acids, absorption enhancers, and/or various other beneficial carriers. The fast-acting oral formulations can create administration benefits. |
|
|
|
Post by compound26 on Oct 2, 2018 16:04:22 GMT -5
A few quick takeaways from Mike’s presentation after listening to it. 1. Mannkind is working with a third party to get Afrezza classified as " ultra-acting" (i.e., its own class); 2. Mannkind will receive another $30 million milestone (plus low double digits royalties) on the second drug they are currently partnering with UT; 3. For Tre-T, Mannkind will receive $25 million milestone in 2019 and another $25 million milestone in 2020. 4. Tre-T’s target market is the whole market (inhale, oral and IV) and potentially “ best in class”. 5. Recapitalization is now complete. There will be no major debt due in the next 36 months. 6. Mannkind has prioritized another four drug candidates that will be further developed in the next 12-18 months. Mike also mentioned something about a (drug) launch every one or two years as a goal towards the end of the presentation. 7. One-drop trial results will be available “ shortly”. 8. Since Mannkind signed contracts with two major PBMs in 2018, they are now working to get local coverage and remove prior-authorizations with respect to these PBMs. 9. For Afrezza, there has been consistent growth since Mannkind launch (Jan. 2017) in numbers of writers (600 to 1100), market share (among Afrezza writers from 3.2% to 4.2%) and cartridge units. 10. Note that, since Mannkind has partnered with UT for two Technosphere drug candidates, in the slide listing the five year growth drivers for the company, Mannkind has added Technosphere Platform as the foundation of the growth drivers. It appears the trial results of Tre-T were really a boost of confidence to Mannkind in their belief of the Technosphere Platform’s potential. Mike referred to the reveal of the trial results as a “flip of the cards” (and the cards turn out to be very favorable).  |
|
|
|
Post by cretin11 on Oct 2, 2018 16:11:36 GMT -5
Money we know of in addition to Afrezza US revenue: Received from UT - 10M UT upfront - 45M in 2 weeks Warrants conversion - 33M within 6 months (if you think if will not happen you are not realistic) UT milestone - 25M within 12 months UT Milestone - 25M within 24 months 138M + Afrezza US net sales of 80M minimum for next 24 months = 2+ year runway The goal is to increase Afrezza world net sales to 100M a year within next 24 months. Thanks for the breakdown buyitonsale, those numbers look promising. About the warrants conversion, is my understanding correct that the share price needs to be above a certain level (is it around $2.30, i can't recall) for that to happen? And you're saying someone is NOT being realistic by thinking that won't happen? We're around $1.70 now, so you're basically saying it's a sure thing to be up over 30% within six months. I'm just trying to make sure I understand your assertion. And while i'd quibble with such a confident expectation for that short a time period (if i'm understanding you), i sure as heck hope you're right. |
|
|
|
Post by sportsrancho on Oct 2, 2018 16:16:59 GMT -5
Thank you Compound! So much appreciated:-)) And for all your hard work over the years! Your mindset your optimism and for being just overall genuinely a happy person!
|
|
|
|
Post by compound26 on Oct 2, 2018 16:26:27 GMT -5
Thank you Compound! So much appreciated:-)) And for all your hard work over the years! Your mindset your optimism and for being just overall genuinely a happy person! Thanks! @sportsrancho. Same to you! Like some members saying that they are addicted to buying shares, I think I might be addicted to listening to these presentations and conference calls. They are very informative.  |
|
|
|
Post by sportsrancho on Oct 2, 2018 16:28:25 GMT -5
Cantor Fitzgerald Global Healthcare Conference $MNKD
|
|
